Cargando…
Extracellular Vesicles-Mimetic Encapsulation Improves Oncolytic Viro-Immunotherapy in Tumors With Low Coxsackie and Adenovirus Receptor
The oncolytic adenovirus (Adv) exhibited poor infection efficiency in tumor cells with low coxsackie and adenovirus receptor (CAR) on the cell surface, which limits the therapeutic efficacy of the Adv-mediated cancer gene therapy. In addition, the abundant adenovirus neutralizing antibodies also abr...
Autores principales: | Zhang, Yonghui, Wu, Junyi, Zhang, Hailin, Wei, Jiwu, Wu, Junhua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7525182/ https://www.ncbi.nlm.nih.gov/pubmed/33042975 http://dx.doi.org/10.3389/fbioe.2020.574007 |
Ejemplares similares
-
Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas
por: Zeng, Jiayi, et al.
Publicado: (2021) -
Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy
por: Palanivelu, Lalitha, et al.
Publicado: (2023) -
Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma
por: Meng, Gang, et al.
Publicado: (2019) -
Recombinant oncolytic adenovirus expressing a soluble PVR elicits long-term antitumor immune surveillance
por: Zhang, Hailin, et al.
Publicado: (2020) -
Rewiring cancer cell death to enhance oncolytic viro-immunotherapy
por: Workenhe, Samuel T, et al.
Publicado: (2013)